EWTXEdgewise Therapeutics, Inc.

HealthcareUSD
$44.38

The financials

Edgewise Therapeutics, Inc. by the numbers

Edgewise Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$62M−$43Mn/a
Net income−$57M−$36Mn/a
Diluted EPS−$0.53−$0.34n/a

Biotechnology

Ranks #11 of 145 by Smart Score

Compare peers
ERAS-0.66%
Erasca, Inc.
CELC-0.47%
Celcuity Inc.
VKTX-2.3%
Viking Therapeutics, Inc.
TNGX+3.5%
Tango Therapeutics, Inc.
ACAD+1.5%
ACADIA Pharmaceuticals Inc.
MANE+1.8%
Veradermics, Incorporated